CHILDREN'S HOSPITAL (PHILADELPHIA)

Funding Organization

Awards Grant

  • A Phase 1 / 2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
  • A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
  • A Phase 2 Multicenter, Single-Arm, Open-Label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (Revlimid®) in Pediatric Subjects from 1 To < 18 Years of Age with Relapsed or Refractory Acute Myeloid Leukemia
  • A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum
  • A Phase I Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA) in Children with Relapsed Refractory Solid Tumors
  • A Phase II Study of Sunitinib in Recurrent or Progressive Brain Tumors in Pediatric and Young Adult Patients
  • A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children with SCID Disorders/ PBMTC PIDTC #6901
  • A Study of the Genetic Causes of Latent Autoimmune Diabetes in Adults
  • AALL 1521; A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2- Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Lukemia
  • AALL0434-Novartis Pharmaceuticals Corporation
  • AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
  • AALL1621- A Phase 2 Study of Inotuzumab Ozogamicin (NSC#772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+B-Acute Lymphoblastic Leukemia(B-ALL)
  • AAML 1031 - Bayer
  • ADVL 1515: A Phase 1 Study of LY2606368, A CHK 1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
  • ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors
  • ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors
  • ADVL 1711: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
  • ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
  • ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
  • ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors
  • ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors
  • ADVL1515: A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors
  • ADVL1721: A Non-Randomized, Open Label, Multi-Center, Phase 1/11 Study of P13K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refactory Solid Tumors or Lymphoma
  • ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory
  • ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory
  • AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
  • AHOD1331-A Randomized Phase III Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents
  • AHOD1721, Risk-based, Response-Adapted, Phase ll Open- Label Trail of Nivolumab+Brentuximab Vedotin(N+Bv) for Children,Adolescents, and Young Adults with Relapsed/ Refractory (R/R) CD30+ Classic Hodgkin Lymphoma (cHL) after Failure of First -Line Therapy, followed by Brentuximab+Bendamustine(Bv+B) for participants with a suboptimal response;CheckMate 744:Checkpoint Pathway and Nivolumab Clinical Trail Evaluation.
  • ALTE11C2 Study - Health Effects after Antracycline and Radiation Therapy (HEART) - Dexazoxane and Prevention of Antracycline-Related Cardiomyopathy
  • ALTE11C2 Study - Health Effects after Antracycline and Radiation Therapy (HEART) - Dexazoxane and Prevention of Antracycline-Related Cardiomyopathy
  • ALTE11C2 Study – Health Effects After Antracycline and Radiation Therapy (HEART) – Dexazoxane and Prevention of Antracycline-Related Cardiomyopathy
  • ALTE11C2-Health Effects after Anthracycline and Radiation Therapy (HEART) - Dexazoxane and Prevention of Antracycline-Related Cardiomyopathy
  • ALTE1621, Reducing Risk of Anthracycline-Related Heart Failure after Childhood Cancer
  • BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement
  • CA 180-372, AALL1122 A Phase 2, Multi-Center, Historically Controlled Study of Dasatinib added to Standard Chemotherapy for Relapsed/Refractory Ph+ALL
  • CCOP Per Case Reimbursement
  • CHOP NCORP - COG Study Chair
  • CHOP NCORP - COG Study Chair
  • CHOP NCORP Research Base
  • CHOP Scientific Council
  • CHOP Scientific Council Chair Grant
  • CHOP Scientific Council Chair Grant
  • CHOP Work Order for STUDY: AALL 1521
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)
  • COG Per Case Reimbursement
  • CTSU: Phase II Supplemental Payments (N02-CM-62212)
  • CTSU: Phase ll Supplemental Payments (N02-CM-62212)
  • Children's Oncology Group Chair's Grant
  • Children's Oncology Group Chair's Grant
  • Children's Oncology Group NCTN Network Group Operations
  • Committee Leadership: NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Acute Myeloid Leukemia Steering Committee
  • Committee Leadership: NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Adolescent-Young Adult Committee Young Investigator
  • Comparative Effectiveness of Therapy for Enthesitis-Related Arthritis
  • Cookies for Kids' Cancer Phase 1 Supplemental
  • Developing a Network to Utilize Administrative and Clinical Data for Childhood, Adolescent and Young Adult Oncology Survivorship Research
  • Distracted Driving in Teens with ADHD
  • Genetic Predictors of AML Treatment Response
  • Hypothemia's Impact on Pharmacology 2
  • Impact of Hypothermia on Midazolam/Morphine Pharmacokinetics
  • Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients
  • Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients
  • Isolation of Friedreich's Ataxia Fibroblast Cell Lines
  • Longitudinal, Multimodal Assessment of Neuropsychological Functioning in Children Diagnosed with High-risk Lymphoblastic Leukemia (HR-ALL); Using Early Changes to Predict Later Impairment (ALTE07C1)
  • NIH COG Phase I Grant
  • NIH COG Phase I Grant
  • Pediatric Intravenous Versus Oral Antibiotic Therapy
  • Per Case Reimbursement and Patient Studies Funds: NIH COG Phase 1 Grant
  • Per Case Reimbursement and Patient Studies Funds: NIH COG Phase 1 Grant
  • Per Case Reimbursement: COG NCORP Research Base
  • Per Case Reimbursement: COG NCORP Research Base
  • Pharmacologic Impact on Sedation Assessments (PISA)
  • Project EveryChild APEC14B1
  • Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT
  • Reduced-Intensity Conditioning for Children and Adults with Hemaphagocytic Syndromes or Selected Primary Immune Deficiencies (RICHI)
  • STUDY: CA180-372: PH II Pediatric - Ph+ ALL
  • Sacroillitis in Children with Juvenile Spondyloarthritis: Improving Diagnosis and Outcomes
  • Scientific Leadership NIH National Clinical Trial Network (NCTN) Grant
  • St. Baldrick's Foundation Supplemental Reimbursement
  • St. Baldricks Fdn Supplemental Reimbursement
  • St.Baldrick's Foundation Support: ALTE15N2 Study
  • Study Chair: NIH National Clinical Trials Network (NCTN) Grant (U10CA18086) Successor to NIH COG Chair Grant (U10CA098543)
  • The Child-Centered Outcomes in Practice and Research (COPR) Center of Excellence: Strengthing the Clinical Validity Evidence Base for PROMIS Measures in Chronically Ill Children
  • The Effects of Sleep Restriction on Adolescent's Pedestrian Safety
  • Unrelated Donor Hematopoietic Cell Transplantation for Children with Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen / BMT CTN Protocol 0601
  • WORKLOAD INTENSITY – NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)
  • Workload Intensity